CTOs on the Move

PaxeraHealth

www.paxerahealth.com

 
PaxeraHealth (Formerly Paxeramed) is a leading healthcare solution developer based in Boston, MA. We develop a full range of medical imaging solutions including PACS, RIS, VNA, multi-modality workstations, mobile App viewers, patient portal, dental PACS, Vet PACS, advanced visualization, Patient engagement and enterprise solutions. Leveraging technology and staying at the forefront of new healthcare IT technological developments is a high priority for PaxeraHealth. The company develops the next generation medical imaging and Patient engagement technologies designed to automate clients` workflow, elevate patient care and cut healthcare costs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Paul Dandrow
Executive Vice President and Chief Technology Officer Profile
Razvan Atanasiu
Chief Technology Officer Profile

Similar Companies

Future Mobility Healthcare Inc

Future Mobility Healthcare Inc is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Continuum Health Services

Continuum Health Services is a Lewiston, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

aClaim

aClaim is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

K B Optics

K B Optics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.